ABC | Volume 113, Nº4, October 2019

Short Editorial Castro & Fontalha Filho Markers of coronary artery disease Arq Bras Cardiol. 2019; 113(4):675-676 1. YusufS,HawkenS,OunpuuS,DansT,AvezumA,LanasF,etal.Effectofpotentially modifiable risk factors associatedwithmyocardial infarction in 52 countries (the INTERHEARTstudy):case-controlstudy.Lancet.2004;364(9438):937-52. 2. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898-904. 3. Redberg RF, Vogel RA, Criqui MH, HerringtonDM, Lima JA, RomanMJ. 34th Bethesda Conference: Task force #3–what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol. 2003;41(11):1886-98. 4. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development forearly detection of cancer. J Natl Cancer Inst. 2001;93(14):1054-61. 5. Abolhasani S, Shahbazloo SV, Saadati HM, Mahmoodi N, Khanbabaei N. Avaliação dos níveis séricos de marcadores de inflamação, fibrinólise e estresse oxidative na predição de doença arterial coronariana:estudo transversal. Arq Bras Cardiol. 2019; 113(4):667-674. 6. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-207. 7. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499-507. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 676